Skip to main content
. 2013 Nov 17;18(1):115–124. doi: 10.1111/jcmm.12170

Figure 4.

Figure 4

Effects of IL-1β and TNF-α upon the survival of motor neuron (SMN) expression levels in human cartilage and chondrocytes. All human normal cartilage explants and cells freshly isolated from these explants were treated for 10 days with either IL-1β or TNF-α (each at either 10 or 100 ng/ml) and processed as described in the Materials and Methods. Explants and cells defined with severe osteoarthritis (OA) were used as positive controls. (A) SMN-specific immunoreactivity on histological explant sections (representative samples; magnification ×20). (B). Safranin O staining of histological explant sections (representative samples; magnification ×2). (C) Percentages of SMN-positive cells on immunohistochemical explant sections (all samples were processed for the analysis) (normal samples: 9.1–12.7% raising at 60.2–63.1%, 73.4–76.8%, 50.8–53.4% and 77.4–78.6% with IL-1β or TNF-α at 10 or 100 ng/ml, respectively; severe OA samples: 84.1–86.4%). (D) SMN concentrations in freshly isolated chondrocytes (all samples were processed for the analysis) (normal samples: 0.10 ± 0.01 ng/mg total proteins raising at 0.18 ± 0.01, 0.22 ± 0.02, 0.14 ± 0.01 and 0.23 ± 0.01 ng/mg total proteins with IL-1β or TNF-α at 10 or 100 ng/ml; severe OA samples: 0.47 ± 0.01 ng/mg total proteins). *Statistically significant difference between groups.